Eliminate Ghost Peaks in UHPLC
Shimadzu has introduced the Ghost Trap™ DS-HP Series Columns which are designed to remove impurities from the solvent and system, enabling highly sensitive and reliable analysis.
Eliminate Ghost Peaks in UHPLC
Shimadzu has introduced the Ghost Trap DS-HP Series Columns which are designed to remove impurities from the solvent and system, enabling highly sensitive and reliable analysis.
These special columns focus on the specific characteristic of the impurities, and their usage can improve the quality of the analytical results dramatically. The Ghost Trap DS-HP columns utilise a new packing material with novel carbon technology, available for aqueous as well as for organic solvents. They can eliminate interference peaks not only from the mobile phase and environment but also from HPLC line by locating the column downstream of GE mixer.
Impurities in the HPLC/UHPLC environment often interfere with the real analytes and badly influence the system performance through their appearance as ghost peaks in the chromatogram. Accumulated impurities may elute from the column during gradient elution. Elimination of these contaminations by dedicated columns avoids time-consuming investigations into the background and nature of the contaminants.
Suitable for UHPLC analysisGhost Trap DS-HP columns offer back pressure tolerance of 100 MPa, well suited to most UHPLC applications in use. They ensure the best performance for high end analysis.
For more information please visit www.shimadzu.eu
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
